

Subject Index

Adjuvant treatment, 27 (E13), 188 (466), 195 (487), 200 (505)
 Clinical practice/guidelines, 123 (253)
 Early breast cancer, 47 (3LB)
 Endocrine therapy, 56 (21, 22, 23), 186 (457)
 Metastatic/advanced breast cancer, 58 (29)
 Quality of life, 125 (260)
 Radiotherapy, 55 (17), 106 (197), 143 (320, 322), 145 (327)

Anastrozole – see under Aromatase inhibitors

Angiogenesis, 41 (E19)
 Thrombospondin, 221 (579)
 VEGF, 220 (577)

Apoptosis – see Tumour biology

Arimidex – see Aromatase inhibitors, anastrozole

Aromatase inhibitors, 113 (222)
 Adjuvant therapy, 69 (67), 78 (101), 115 (229), 116 (230), 120 (243), 121 (246), 122 (248), 200 (505)
 Anastrozole, 52 (9), 71 (73), 118 (236), 120 (243), 122 (248), 251, 126 (263, 264), 127 (265), 176 (421), 178 (428), 201 (508)
 Early breast cancer, 52 (9), 122 (251), 197 (494)
 Exemestane, 52 (9), 178 (428), 198 (496)
 Letrozole, 52 (9), 117 (234), 118 (236), 119 (239), 126 (264), 176 (422), 178 (428)
 Metastatic/advanced breast cancer, 178 (428)
 Neoadjuvant therapy, 128 (270)
 Post-menopausal patients, 78 (101), 122 (248), 199 (499, 500)
 Tamoxifen, 71 (73), 75 (87), 122 (251), 126 (263), 130 (276), 198 (496)

Axillary lymph nodes

Adjuvant therapy, 143 (322)
 Biopsy, 129 (274), 147 (334), 153 (354), 155 (362)
 Ductal carcinoma in situ, 148 (338)
 Early breast cancer, 170 (401, 403), 191 (476), 215 (560)
 Lymph node dissection, 99 (177), 107 (201), 135 (294), 147 (335), 149 (340, 342), 150 (345), 151 (347, 349), 152 (351, 352), 153 (353, 354, 355, 356), 154 (359), 156 (364), 157 (367), 170 (403), 202 (509), 203 (512), 205 (520), 208 (532, 533), 209 (537), 214 (557), 215 (560, 562)
 Lymphoedema, 151 (349), 214 (557)
 Micrometastasis, 102 (187), 151 (346), 155 (363)
 Prognostic factor, 99 (177), 135 (291), 138 (302), 153 (355), 156 (366), 157 (368), 182 (442), 187 (461), 194 (486)
 Radiotherapy, 143 (322)

Biopsy and Biopsy techniques, 113 (221), 131 (278), 147 (334), 169 (397)
 Core needle, 63 (44), 64 (49), 140 (311), 141 (315)
 Fine needle Aspiration, 60 (35), 129 (274)
 Radioguided, 148 (339)
 Ultrasound guided, 66 (55), 77 (96), 88 (138)
 VAC mammotone, 65 (53), 66 (55), 77 (96), 141 (315)
 Wire-guided, 212 (547)

Bisphosphonates, 108 (205), 129 (273), 130 (276), 197 (493)
 Ibandronate, 72 (77)
 Zoledronate, 69 (67), 120 (242), 197 (494), 201 (507)

Bone marrow metastasis, 61 (38), 69 (66), 100 (183), 108 (205), 114 (226), 120 (242), 130 (277), 140 (310), 168 (393), 194 (484)

Bone metastasis (see also Metastatic/advanced disease)
 Bisphosphonates, 99 (178), 108 (205), 129 (273), 201 (507)
 Prognostic factors, 174 (414), 175 (417)

Brain metastasis (see also Metastatic/advanced disease), 109 (207), 146 (332), 173 (411, 413), 175 (419), 176 (423), 183 (448), 221 (580)

Breast conserving surgery, 75 (89), 90 (146), 202 (509), 207 (528)
 Aesthetic outcome, 53 (14), 156 (364), 203 (512), 206 (526), 207 (527), 209 (536), 210 (541), 214 (555, 556)
 Breast reconstruction, 203 (512), 204 (516), 205 (523), 209 (536), 211 (544), 214 (556)
 Chemoradiotherapy, 213 (553)
 Ductal carcinoma in situ, 207 (530)
 Early breast cancer, 117 (234), 152 (352), 203 (512)
 Endoscopic surgery, 213 (553)
 Local recurrence, 116 (231), 127 (267), 132 (285), 135 (293), 150 (344), 204 (517)
 Neo-adjuvant chemotherapy, 204 (519)
 Non-palpable breast tumours, 208 (531)
 Radiotherapy, 55 (17), 121 (247), 132 (285), 133 (286), 134 (289), 142 (317), 145 (326), 206 (524), 207 (527), 211 (546)
 Small breast cancer, 207 (529)
 Surgical practice, 64 (48), 210 (541)

Breast Units, 53 (13), 68 (63), 73 (80), 77 (97), 165 (383, 384), 166 (388), 167 (392)

c-erbB-2 – see Her-2/neu

*Page numbers are followed by the abstract numbers in parentheses.

Chemotherapy/adjuvant chemotherapy, 27 (E13), 58 (28), 117 (235), 200 (505), 218 (571)

Adriamycin, 125 (259)
 Antracyclines, 183 (449), 197 (495), 218 (569)
 Capecitabine, 47 (1LB), 108 (203), 109 (209), 129 (272), 171 (405), 173 (412), 175 (419, 420), 177 (424, 425), 200 (503), 216 (565), 220 (578)
 Chemosensitivity prediction, 65 (52)
 Doxorubicin, 58 (29), 177 (424), 178 (429)
 Epirubicin, 108 (203), 116 (232), 119 (241), 121 (245), 136 (296)
 5FU, 55 (18), 121 (245), 172 (407)
 Gemcitabine, 118 (238), 119 (241), 136 (296), 174 (415), 175 (420), 178 (430), 179 (432), 217 (568)
 Locally advanced breast cancer, 60 (36), 119 (241), 154 (359)
 Neoadjuvant chemotherapy, 60 (36), 62 (41), 66 (57), 101 (186), 106 (196), 107 (200, 201, 202), 112 (216), 113 (221), 116 (231), 119 (240, 241), 125 (259), 127 (267), 129 (272), 130 (275), 148 (336), 150 (345), 154 (359), 190 (473), 191 (477), 209 (535), 215 (562)
 Predictive factors, 55 (18, 19), 191 (474), 201 (508)
 Quality of life, 94 (159), 200 (504)
 Taxanes, 118 (237), 196 (490)
 Toxicity and side effects, 68 (62), 69 (67)

Clinical practice/guidelines/attitudes, 78 (100), 91 (148), 157 (369), 158 (374)

Breast cancer management, 2 (E1), 11 (E5), 25 (E11), 26 (E12), 27 (E13), 39 (E18), 51 (5), 52 (6), 53 (13), 67 (59), 68 (61, 63), 69 (65), 88 (139), 89 (142), 115 (229), 123 (253), 125 (258, 261), 126 (262), 131 (279), 145 (327), 163 (376), 165 (382, 384), 166 (387, 388, 389), 167 (390), 391, 392), 169 (399), 181 (440), 182 (443), 203 (513), 205 (520), 210 (539)
 Data management, 66 (56), 72 (78), 73 (80), 164 (381), 165 (383)
 Education, 58 (27, 28)
 Guidelines, 89 (142), 112 (217), 116 (230), 125 (258, 261), 126 (262), 131 (279), 145 (327), 146 (331), 159 (375), 164 (381), 166 (387, 388, 389), 181 (440), 182 (443), 205 (520), 210 (539)
 Quality control, 19 (E9), 23 (E10), 51 (1), 58 (28), 69 (65), 112 (217), 116 (230), 125 (258), 165 (383), 203 (513)

Clinical trials, 37 (E17), 47 (2LB, 3LB), 92 (151), 109 (209), 111 (214), 113 (220), 114 (224), 115 (227), 116 (231, 232), 117 (234, 235), 119 (239, 240), 121 (245), 128 (271), 141 (314), 147 (335), 165 (385), 175 (418), 176 (421), 177 (424, 425), 178 (427), 188 (467), 192 (478), 194 (486), 196 (490, 492), 197 (495), 218 (569), 220 (578)**Clodronate – see Bisphosphonates****Complementary and alternative treatment**, 196 (491)**Computers/simulation**, 63 (45), 128 (271), 153 (353), 156 (364)**Costs and cost control**, 51 (1, 3, 5), 52 (6), 64 (50), 67 (58), 69 (67), 73 (82), 91 (147), 94 (161), 114 (224), 126 (264), 135 (292), 157 (369), 166 (389), 167 (391), 176 (423)**Diagnosis**, 42 (E20), 77 (95), 82 (116), 87 (133), 98 (173), 222 (584)
 Atypical ductal hyperplasia, 77 (98), 141 (315)

Axillary lymph node involvement, 60 (35), 147 (334), 148 (336, 338), 149 (340), 152 (350), 153 (354), 155 (362)
 Biopsy techniques, 9 (E4), 60 (35), 63 (44), 64 (49), 65 (53), 77 (96), 212 (547)
 Delayed diagnosis, 75 (90)
 Ductal carcinoma in situ, 35 (E16)
 Metastasis, 54 (15), 61 (39), 138 (305), 140 (310), 151 (348), 216 (563)
 Nipple discharge, 62 (40)
 Non-palpable lesions, 159 (375)
 Recurrent disease, 137 (300), 147 (334), 150 (344), 153 (354), 155 (362)
 RT-PCR techniques, 61 (38), 62 (40), 81 (111), 82 (115), 140 (312)
 Triple diagnostic approach, 87 (134), 134 (290), 183 (447)

Diagnostic imaging

Lymphoscintigraphy, 148 (337), 155 (360)
 Mammography, 4 (E2), 63 (45), 64 (50), 65 (51), 98 (175)
 MRI, 4 (E2), 54 (16), 60 (36), 61 (39), 62 (42), 64 (47), 65 (52), 66 (57), 130 (275), 133 (287)
 PET/CT, 61 (37, 39), 62 (41), 64 (48), 148 (337), 216 (563)
 Ultrasonography, 4 (E2), 61 (39), 62 (43)

Docetaxel, 47 (3LB), 200 (502), 222 (582)

Adjuvant therapy, 58 (29), 114 (224), 116 (232), 118 (238), 122 (250), 128 (268)
 Apoptosis, 100 (181)
 Doxorubicin, 122 (250), 124 (257), 128 (268)
 Metastatic/advanced disease, 109 (209), 136 (298), 172 (407, 409), 178 (429), 179 (434), 186 (459), 217 (567)
 Neoadjuvant therapy, 47 (1LB), 108 (203), 121 (245), 125 (259), 136 (296)
 Preoperative treatment, 136 (298)

Drug resistance, 53 (12), 84 (124), 100 (182), 105 (191)**Ductal carcinoma in situ**, 131 (280), 132 (284)

Axillary lymph node dissection, 170 (403)
 Breast conserving surgery, 133 (286)
 Histopathology/classification, 35 (E16), 80 (109), 148 (338)
 Local recurrence, 135 (293), 169 (399)
 Mastectomy, 132 (283)
 Prognostic factors, 130 (277), 131 (278, 281), 169 (399)
 Screening, 132 (282)
 Ultrasound, 132 (282)

Early breast cancer, 65 (52), 158 (373), 175 (417), 212 (549)

Adjuvant chemotherapy, 118 (236)
 Adjuvant tamoxifen, 119 (239)
 Axillary lymph node dissection, 215 (560)
 Breast conserving surgery, 47 (2LB), 145 (327), 152 (352)
 Elderly/geriatric patients, 118 (236), 119 (239)
 Fenretinide, 120 (242)
 Ipsilateral/contralateral breast cancer, 64 (50), 66 (54)
 Radiotherapy, 47 (2LB), 144 (325)
 Second cancers, 90 (145)

Elderly/geriatric patient care, 72 (76), 78 (99), 120 (243), 121 (246, 247), 122 (248), 130 (276), 135 (292), 163 (376), 170 (401, 402), 174 (415), 175 (417), 177 (426), 181 (440), 182 (444)**Endocrine therapy/adjuvant endocrine therapy**, 52 (10, 7, 8), 55 (20), 114 (225), 115 (227), 123 (252), 127 (266), 150 (345), 169 (398), 176 (422), 179 (431), 180 (435), 186 (457), 193 (481), 196 (491)

- EORTC trials**, 73 (82), 132 (285), 134 (289), 147 (335), 194 (485)
- Epidemiological studies**, 11 (E5), 57 (25, 26), 66 (54), 70 (68, 70), 71 (72, 75), 72 (76), 73 (79, 81), 74 (83), 75 (88, 89, 90), 76 (91, 92), 77 (97), 78 (100, 102), 85 (125), 96 (166, 168), 97 (169, 170, 171), 112 (217), 125 (260), 137 (300), 167 (390), 185 (453), 212 (549)
- Estrogen and progesterone receptors**, 71 (75), 76 (94), 81 (112), 84 (122), 85 (128), 87 (134), 102 (189), 115 (227), 122 (249), 123 (252), 125 (261), 138 (304), 140 (311), 164 (378), 171 (404), 182 (443), 183 (447, 449), 185 (455, 456), 186 (457), 190 (471, 472)
- Exemestane – see under Aromatase inhibitors**
- Familial cancer/genetic testing**
 BRCA1/BRCA2 carriers, 70 (69), 79 (103), 83 (121), 86 (132), 87 (136), 91 (147, 149), 94 (161), 109 (208), 164 (380), 169 (398), 184 (450)
 BRCA1/BRCA2 prevalence/screening, 7 (E3), 85 (125)
 Genetic counselling, 74 (85), 83 (121)
 Mammography, 95 (165)
 MRI imaging, 95 (164, 165)
 Ovarian cancer, 86 (132)
 Prophylactic surgery, 169 (398)
 Psychological morbidity, 91 (150)
 Risk estimation, 70 (69, 71), 79 (103), 169 (398)
 Surveillance, 87 (136), 94 (161), 95 (164, 165)
- Her-2/neu**, 31 (E14), 39 (E18), 120 (244), 154 (358), 168 (396)
 ER positive tumours, 85 (128)
 FISH, 87 (135), 139 (307)
 Gene expression profiling, 81 (114), 86 (130)
 Immunohistochemistry, 87 (135)
 Predictive/prognostic factor, 81 (114), 88 (137), 138 (304), 175 (419)
 Signal transduction, 164 (378)
 Trastuzumab, 136 (298), 169 (400), 217 (566), 221 (580, 581), 222 (583)
- Herceptin – see Trastuzumab**
- Histology**, 79 (105, 106), 80 (107, 108, 109), 81 (111, 112, 113, 114), 82 (115), 83 (119), 85 (127), 87 (135), 102 (189), 138 (303), 139 (307, 308), 157 (367), 194 (485)
- Immunology and Immunotherapy**, 100 (183)
 Chemotherapy effects, 101 (186)
 Immunotherapy, 41 (E19), 108 (205), 117 (233), 217 (566, 567), 218 (571), 219 (573, 574), 220 (577, 578), 221 (580, 581)
- Letrozole – see under Aromatase inhibitors**
- Lymphoedema**, 151 (349), 208 (533)
- Male breast cancer**, 71 (72), 78 (102), 85 (125), 86 (130), 113 (219), 180 (438)
- Metastatic/advanced breast cancer**, 26 (E12), 61 (38), 109 (206, 207), 137 (299, 301), 138 (303, 305), 139 (306), 146 (332), 153 (356), 168 (396), 173 (413), 174 (415), 175 (419), 177 (424), 179 (433), 194 (484), 205 (521), 216 (563)
 Adjuvant chemotherapy, 109 (208), 216 (565)
- Aromatase inhibitors, 176 (421), 178 (428), 179 (431)
 Bisphosphonates, 99 (178), 129 (273), 197 (493), 201 (507)
 Bone (see also Bone metastasis), 99 (178), 129 (273), 174 (414), 175 (417), 197 (493), 201 (507)
 Cardiotoxicity, 109 (209), 122 (248), 143 (320), 219 (574)
 Clinical management, 215 (560)
 Docetaxel, 67 (58), 172 (407), 178 (429), 179 (434), 217 (567), 222 (582)
 Endocrine therapy, 176 (422), 179 (431), 180 (435), 190 (471)
 Gemcitabine, 136 (296), 175 (420), 178 (430), 179 (432), 217 (568)
 High-dose chemotherapy, 111 (213)
 Paclitaxel, 67 (58), 171 (406), 172 (408, 409, 410), 174 (416), 177 (426), 178 (427), 180 (437), 200 (503), 217 (568), 218 (569), 219 (573), 220 (577), 222 (582)
 Prognostic factors, 140 (310), 141 (314), 156 (366), 171 (404), 174 (414), 180 (436, 437), 181 (439), 183 (448), 189 (468), 216 (564)
 Trastuzumab, 169 (400), 171 (405), 176 (423), 179 (434), 180 (436), 192 (479), 193 (480), 220 (578), 221 (580, 581)
 Vinorelbine, 172 (407), 173 (411, 412), 175 (418), 177 (425), 179 (432), 220 (578)
- Nursing**, 67 (59), 88 (138, 139), 167 (391)
- Paclitaxel**, 67 (58), 171 (406), 174 (416), 177 (426), 178 (427), 180 (437), 186 (459), 200 (502, 503), 217 (568), 218 (569), 219 (573), 220 (577), 222 (582)
- Palliative care**, 93 (154), 178 (430)
- Pathology**, 9 (E4), 31 (E14), 54 (15), 59 (30), 70 (70), 79 (104, 105, 106), 80 (108, 109), 81 (112, 113), 82 (116), 83 (120), 86 (131), 87 (133), 101 (185), 114 (223, 226), 138 (302, 303, 305), 139 (306, 308, 309), 140 (311, 312), 141 (313, 315), 148 (339), 149 (341), 150 (343), 151 (346, 347), 152 (351), 154 (357), 157 (367), 158 (371, 373), 166 (386), 168 (393, 394, 396), 182 (444), 183 (445, 449), 184 (451), 185 (455, 456), 186 (458), 194 (485), 222 (584)
 Inprint cytology, 139 (307), 151 (348)
 Invasive lobular cancer – tumour grade, 133 (287)
 Quality assurance, 164 (381)
- Predictive factors**, 53 (12), 69 (66), 112 (216), 153 (356), 180 (438), 181 (441), 182 (442), 193 (483), 195 (488), 204 (518)
 BCAR1/p130Cas gene, 91 (147, 149)
 Bcl-2, 186 (458)
 Bone turnover markers, 201 (508)
 CD44 v6 & v9, 99 (179), 105 (194), 108 (204)
 Estrogen receptor, 112 (218), 122 (249)
 Gene expression profiling, 55 (19), 56 (21, 22), 85 (126), 88 (137), 193 (481)
 Genetic markers, 55 (18, 19, 20), 56 (21, 22), 59 (31), 74 (85), 105 (191)
 Her-2/neu, 105 (191), 115 (228), 120 (244), 122 (249), 123 (254), 173 (413), 183 (448), 186 (459), 190 (473), 191 (475, 477), 193 (480)
 New markers, 60 (33, 34)
 Response to therapy, 216 (564)
 Sentinel lymph node, 149 (340), 157 (368)
 VEGF, 185 (454)
- Pregnancy and fertility**, 63 (46), 68 (61), 94 (158), 105 (190), 184 (452), 201 (506)

Prevention, 7 (E3)

Chemoprevention, 72 (77), 75 (87)
 Lifestyle factors, 76 (92)
 Prophylactic surgery, 91 (147)
 Public attitudes, 74 (84)
 Second cancer, 73 (81)

Prognostic factors, 9 (E4), 58 (29), 69 (66), 74 (83, 86), 86 (129), 88 (137), 100 (183), 101 (186), 113 (219), 140 (310), 141 (314), 183 (446, 447), 186 (457, 458, 460), 187 (464), 188 (465), 189 (468, 470), 193 (483), 194 (484), 195 (487), 205 (521)

Angiogenesis, 59 (32)
 Axillary lymph node status, 67 (60), 135 (291), 138 (302), 157 (368), 181 (439, 441), 182 (442), 184 (451), 187 (461), 191 (474, 476), 194 (486), 195 (488)
 CA 15-3, 182 (444), 189 (469)
 EGFR, 86 (130), 187 (463)
 Estrogen receptor, 87 (134), 122 (249), 171 (404), 182 (444), 183 (447, 449), 185 (455, 456), 190 (471)
 Her-2/neu, 87 (134), 117 (233), 122 (249), 123 (252, 254), 173 (413), 180 (436), 183 (448, 449), 185 (455, 456), 186 (459), 190 (472, 473), 191 (475, 477)
 Invasive lobular cancer – tumour grade, 133 (287)
 New markers, 59 (31, 32), 60 (33, 34), 82 (117), 83 (118), 166 (386), 182 (444), 183 (446)
 P53, 172 (408), 183 (449)
 Plasminogen activator, 102 (187), 188 (467)
 Tumour location, 193 (482)
 Tumour size, 180 (438), 182 (442), 187 (462)
 Urokinase-type plasminogen activator/inhibitor (uPA/PAI-1), 102 (187), 192 (478)
 VEGF, 41 (E19), 80 (107), 185 (454)
 Vitamin D receptor, 76 (93)
 Young age (<35 yrs), 76 (94), 94 (158), 96 (167), 125 (258), 184 (450, 452), 205 (522)

Psycho-oncology, 91 (148), 127 (265)

Breast reconstruction, 212 (549)
 Counselling, 67 (59)
 Education, 56 (23), 89 (140), 110 (210)
 Family life, 93 (154, 155, 157)
 Follow-up, 67 (59), 196 (490)
 Mammographic screening, 9 (E4)
 Patient/family communications, 92 (151), 93 (157)
 Patient survey, 92 (151)
 Psychological morbidity, 90 (146), 91 (150), 92 (152, 153), 93 (155, 156), 94 (160), 110 (211), 198 (498)
 Psychosocial support, 90 (145, 146), 92 (153), 93 (154, 155), 94 (160), 110 (212), 198 (498)
 Public awareness, 57 (24, 25, 26), 74 (84), 96 (166)
 Quality of life, 52 (10), 73 (82), 89 (141, 143), 90 (144), 92 (152), 93 (154, 155), 94 (159), 111 (214), 125 (260), 171 (406), 176 (421), 216 (565)
 Rehabilitation, 92 (153), 111 (213), 157 (369), 163 (376)

Radiotherapy/adjuvant radiotherapy, 111 (215), 158 (372), 199 (501)

Axillary treatment, 143 (322), 147 (335)
 Brachytherapy, 142 (317), 206 (524)
 Breast conserving therapy, 106 (197), 121 (247), 132 (285), 133 (286), 142 (317), 143 (319), 144 (323, 325), 145 (326), 204 (517), 211 (546)
 3D planning, 142 (318), 144 (324)
 Dose delivery, 132 (285), 142 (316, 318), 143 (319, 320, 321), 144 (323, 324, 325), 145 (327, 328, 329), 146 (330, 332)

Ductal carcinoma in situ, 132 (283, 284), 133 (286), 169 (399)
 Early breast cancer, 111 (214), 117 (234), 144 (323, 325)
 Internal mammary lymph nodes, 143 (322)
 Intra-operative radiotherapy, 146 (333), 207 (527)
 Locally advanced disease, 133 (288), 134 (289), 137 (299)
 Metastatic disease, 146 (332), 173 (411)
 Neoadjuvant radiotherapy, 206 (524)
 Quality assurance, 13 (E6), 146 (331)
 Radiation-induced cancer, 96 (167), 136 (295)

Rare tumours, 185 (454)

Inflammatory breast cancer, 76 (91), 88 (137), 107 (202), 115 (228), 118 (237), 125 (259), 126 (262), 136 (298), 139 (306)

Screening, 7 (E3), 97 (172)

Clinical breast examination, 63 (46), 96 (166), 212 (547)
 Early detection rate, 48 (5LB), 96 (168), 97 (169, 170)
 Frequency of screens, 48 (4LB)
 Mammography, 4 (E2), 11 (E5), 33 (E15), 48 (5LB), 64 (50), 95 (162, 163), 96 (168), 97 (169, 170, 171), 212 (547)
 MRI, 4 (E2), 95 (164)
 Public awareness, 96 (166)
 Recommendations, 96 (167)
 Surveillance, 96 (167)

Sentinel lymph node, 107 (201), 148 (338), 150 (343), 151 (349), 152 (350), 157 (370), 212 (550), 214 (557)

After previous excision biopsy, 149 (342), 159 (375)
 Alternative strategy, 149 (342)
 Internal mammary, 98 (174)
 Intra-operative pathology assessment, 149 (341), 151 (347, 348), 152 (351), 154 (357), 158 (371, 374)
 Lymphatic flow, 98 (174), 99 (176)
 Metastasis assessment, 54 (15), 147 (335), 151 (346), 152 (351), 153 (353), 154 (359), 155 (363)
 Model of predictive value, 148 (336), 150 (344, 345), 153 (353, 354), 154 (357), 155 (362), 157 (368), 159 (375), 170 (403)
 Pre-operative technique, 131 (279), 148 (337), 152 (352), 154 (357), 155 (360), 158 (374)
 Predictive factors for involvement, 113 (221), 149 (340), 155 (363), 156 (366)
 Radioactive tracers, 155 (360), 169 (397)
 Radiopharmaceutical/dye, 148 (339), 158 (373, 374), 169 (397), 170 (403)
 Radiotherapy of the axilla, 145 (329)
 Validation study, 147 (334), 157 (369), 158 (371, 373), 159 (375)
 Visualisation, 148 (337)

Side effects and complications, 47 (1LB), 52 (10), 68 (62), 71 (73), 78 (101), 109 (209), 111 (215), 113 (222), 116 (232), 117 (233), 118 (238), 122 (248, 251), 124 (255, 256, 257), 126 (263), 128 (268), 130 (276), 132 (284), 136 (295), 137 (301), 142 (318), 143 (320, 322), 145 (328), 158 (372), 173 (412), 195 (489), 198 (496, 497, 498), 199 (499, 500, 501), 200 (502, 503, 504, 505), 201 (506, 507, 508), 202 (509, 510, 511), 208 (533), 209 (535), 210 (540), 211 (545), 214 (555, 557, 558), 219 (574)**Signal transduction pathways – see under Tumour biology****Small breast cancer, 71 (74)**

- Staging**, 35 (E16), 54 (15, 16), 61 (38), 69 (66), 85 (128), 96 (168), 98 (174), 99 (176, 177), 129 (274), 130 (277), 131 (279, 281), 133 (287), 135 (291), 150 (343, 345), 151 (346), 155 (361), 156 (365), 170 (403), 187 (462), 203 (514), 205 (521), 216 (563)
- Supportive treatment**, 128 (269), 195 (489), 196 (491, 492), 198 (497), 202 (510)
- Surgery**, 54 (16), 109 (206), 148 (337), 158 (374), 167 (391), 179 (433), 203 (514), 205 (523)
 Adjuvant chemotherapy, 117 (235), 170 (402)
 Anaesthesia, 212 (550)
 Breast reconstruction, 15 (E7), 89 (141, 143), 90 (144), 155 (361), 203 (512), 204 (515, 516), 206 (525, 526), 208 (534), 209 (537, 538), 210 (540, 542), 211 (544), 212 (549), 213 (554), 214 (556), 215 (561)
 Cancer recurrence, 135 (293, 294), 136 (297), 204 (517)
 Ductal carcinoma in situ, 207 (530)
 Elderly/geriatric patient care, 170 (402)
 Endoscopic surgery, 213 (553)
 Locally advanced cancer, 133 (288), 135 (293, 294), 137 (301), 169 (400), 204 (519), 215 (560)
 Mastectomy, 89 (141), 90 (146), 91 (149), 132 (283), 133 (288), 136 (297), 202 (509), 204 (518), 205 (522), 209 (535), 213 (552), 214 (555, 558), 215 (559, 561)
 MRI guided surgery, 106 (196)
 Neoadjuvant therapy, 53 (13), 62 (41), 169 (400)
 Non-palpable lesions, 208 (531), 212 (548)
 Parasternal lymphadenectomy, 205 (521)
 Prophylactic surgery, 169 (398)
 Quality assurance, 15 (E7), 58 (27), 62 (42), 167 (392), 203 (513), 210 (539), 213 (551)
 Radioguided surgery, 212 (548)
 Sentinel lymph node dissection (see also Sentinel lymph node), 71 (74), 147 (335), 148 (336), 149 (340), 150 (345), 151 (347, 349), 152 (350), 153 (353)
 Small breast tumours, 145 (327), 207 (528, 529)
 Surgical margins, 150 (343), 207 (530)
 Surgical techniques, 206 (525), 207 (528), 208 (531, 532, 533, 534), 209 (537, 538), 210 (540, 542), 211 (543, 544, 545, 546), 212 (548), 213 (551, 554), 214 (555, 556), 215 (559, 560, 561)
- Surgical margins – see Surgery**
- Tamoxifen therapy**, 52 (8), 213 (552)
 Adjuvant tamoxifen, 53 (12), 55 (17), 56 (21, 22, 23), 84 (124), 113 (220), 114 (225), 170 (402)
 Aromatase inhibitors, 198 (496)
 Cancer prevention, 75 (87)
 Metastatic/advanced breast cancer, 56 (21, 22)
 Post-menopausal patients, 55 (20), 56 (21, 22)
 Predictive factor, 56 (21, 22), 112 (218), 140 (312)
 Toxicity and side effects, 71 (73), 202 (511)
- Taxanes – see Docetaxel and Paclitaxel**
- Trastuzumab**, 108 (203), 115 (228)
 Early breast cancer, 47 (1LB)
 First line/single agent, 169 (400)
 Metastatic disease, 109 (209), 172 (410), 175 (418), 176 (423), 178 (430), 179 (434), 180 (436), 192 (479), 217 (566), 221 (580, 581), 222 (583)
 Paclitaxel, 117 (233)
 Toxicity and side effects, 111 (215), 117 (233), 124 (255), 142 (318), 217 (566), 219 (574)
 Tumour biology, 136 (298)
 Vinorelbine, 136 (296), 175 (418), 218 (570), 220 (578)
- Triple negative breast cancer**, 165 (385), 166 (386, 387), 187 (464), 188 (465), 218 (571), 220 (576)
- Tumour biology**, 83 (120), 87 (133), 99 (179), 100 (180), 163 (377), 183 (445, 446), 204 (515)
 Angiogenesis, 62 (43), 114 (225), 221 (579)
 Apoptosis, 85 (127), 100 (181)
 Carcinogenesis, 68 (64), 76 (92), 81 (113), 102 (188)
 Drug development, 84 (123), 219 (572)
 Drug resistance, 100 (182), 119 (240), 218 (570), 219 (575)
 Estrogen receptors, 68 (64), 80 (108), 81 (112), 102 (189), 112 (218), 114 (223, 226), 115 (228), 117 (235), 138 (304), 164 (378)
 Gene expression, 17 (E8), 31 (E14), 80 (110), 81 (113), 82 (117), 86 (131), 88 (137), 98 (173), 100 (182), 101 (184), 105 (192, 194), 106 (195), 139 (308), 141 (313), 187 (463), 188 (466), 193 (480), 219 (575), 222 (584)
 Gene mutations, 68 (64), 82 (115), 83 (121), 85 (126), 139 (309)
 Growth factors and growth-factor receptors, 59 (30), 60 (33), 80 (107, 110), 86 (131), 120 (244), 187 (463), 218 (571), 221 (579)
 Matrix metalloproteinases (MMP), 86 (129)
 Metastasis, 168 (393, 394, 396)
 P53, 139 (309)
 Proteomics, 79 (104), 82 (116), 84 (122)
 Rb protein family, 187 (463)
 Signal transduction pathways, 164 (378)
 Tumour markers, 79 (105, 106), 82 (116), 83 (118, 119), 136 (298), 140 (310), 182 (444)
 Urokinase-type plasminogen activator/inhibitor (uPA/PAI-1), 2 (E1), 188 (467), 192 (478)
 VEGF, 41 (E19), 80 (107)
- Tyrosine kinase inhibitors**, 220 (576)
 Lapatinib, 171 (406), 175 (419), 200 (502), 216 (565)
- Young patients**, 158 (372), 171 (405), 182 (442, 443), 184 (450, 452), 194 (485), 205 (522)
- Zoledronate – see Bisphosphonates**